Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 20/20 | 1.00 |
| ▸ | CTSK | P43235 | 16/20 | 0.85 |
| ▸ | CTSL | P07711 | 15/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3018612 | 1.00 | CTSS (1.00) | CTSSCTSKCTSL | |
| SCHEMBL3018609 | 1.00 | CTSS (1.00) | CTSSCTSKCTSL | |
| SCHEMBL5494426 | 0.95 | CTSS (0.91) | CTSSCTSKCTSL | |
| SCHEMBL5494424 | 0.95 | CTSS (0.91) | CTSSCTSKCTSL | |
| SCHEMBL3018165 | 0.92 | CTSS (1.00) | CTSSCTSKCTSL | |
| SCHEMBL3018173 | 0.92 | CTSS (1.00) | CTSSCTSKCTSL | |
| SCHEMBL3018170 | 0.92 | CTSS (1.00) | CTSSCTSKCTSL | |
| SCHEMBL3016405 | 0.89 | CTSS (1.00) | CTSSCTSKCTSL | |
| SCHEMBL3016402 | 0.89 | CTSS (1.00) | CTSSCTSKCTSL | |
| SCHEMBL3016400 | 0.89 | CTSS (1.00) | CTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7314872-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-01-01 | — | — | US | claimed |
| US-20050113356-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-05-26 | — | — | US | claimed |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2010-08-12 | — | — | US | disclosed |
| US-7732449-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2010-06-08 | — | — | US | disclosed |
| EP-1658267-B1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-10-14 | — | — | EP | disclosed |
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-7501408-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2009-03-10 | — | — | US | disclosed |
| US-20080108595-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7314872-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-01-01 | — | — | US | disclosed |
| EP-1658267-A4 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2007-08-01 | — | — | EP | disclosed |
| EP-1658267-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2006-05-24 | — | — | EP | disclosed |
| US-20050113356-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2005-05-26 | — | — | US | disclosed |
| WO-2005034848-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137570-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSK 9/4885CTSL 11/4885 |
| US-20080108595-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSK 9/4885CTSL 11/4885 |
| US-20050113356-A1 | Inhibitors of cathepsin S | CTSS, CTSB, CTSZ | CTSS 1/4885CTSK 9/4885CTSL 11/4885 |
| US-20100204200-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSE, CTSV | CTSS 1/4885CTSK 10/4885CTSL 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.